Impact of ADAR-induced editing of minor viral RNA populations on replication and transmission of SARS-CoV-2.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35064076.
- Also identified by DOI 10.1073/pnas.2112663119 and PMC identifier 8833170.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Adenosine deaminases acting on RNA (ADAR) are RNA-editing enzymes that may restrict viral infection. We have utilized deep sequencing to determine adenosine to guanine (A→G) mutations, signifying ADAR activity, in clinical samples retrieved from 93 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients in the early phase of the COVID-19 pandemic. A→G mutations were detected in 0.035% (median) of RNA residues and were predominantly nonsynonymous. These mutations were rarely detected in the major viral population but were abundant in minor viral populations in which A→G was more prevalent than any other mutation (<i>P</i> < 0.001). The A→G substitutions accumulated in the spike protein gene at positions corresponding to amino acids 505 to 510 in the receptor binding motif and at amino acids 650 to 655. The frequency of A→G mutations in minor viral populations was significantly associated with low viral load (<i>P</i> < 0.001). We additionally analyzed A→G mutations in 288,247 SARS-CoV-2 major (consensus) sequences representing the dominant viral population. The A→G mutations observed in minor viral populations in the initial patient cohort were increasingly detected in European consensus sequences between March and June 2020 (<i>P</i> < 0.001) followed by a decline of these mutations in autumn and early winter (<i>P</i> < 0.001). We propose that ADAR-induced deamination of RNA is a significant source of mutated SARS-CoV-2 and hypothesize that the degree of RNA deamination may determine or reflect viral fitness and infectivity.
Medical subject headings
- Adenosine Deaminase
- COVID-19
- Point Mutation
- RNA Editing
- RNA, Viral
- RNA-Binding Proteins
- SARS-CoV-2
- Spike Glycoprotein, Coronavirus